The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Noxopharm (NOX) publishes preliminary data from its IONIC investigator-initiated pilot trial for its oncology drug Veyonda
  • IONIC is exploring Veyonda’s potential to increase the efficiency of Opdivo, an immune inhibitor used to treat solid tumours
  • The company completed phase one of the trial, with the findings being published ahead of the American Society of Clinical Oncology’s (ASCO) annual meeting
  • Noxopharm is developing its partnerships with researchers to build two new technology platforms, Chroma and Sofra
  • Noxopharm last traded at 4.9 cents at 3:15 pm AEST

Biotech company Noxopharm (NOX) has published preliminary data from its IONIC investigator-initiated pilot trial for oncology drug Veyonda.

IONIC is exploring the Veyonda’s potential to increase the activity of Bristol Myers Squibb’s immune checkpoint inhibitor Opdivo (nivolumab) for patients with solid tumours.

Noxopharm’s phase one results will be published in the form of an abstract at the American Society of Clinical Oncology’s (ASCO) annual meeting, which will take place in Chicago in June.

The annual ASCO meeting is one of the largest gathering of oncology professionals, exposing the trial to an array of industry professionals.

Bristol Myers Squibb and Noxopharm completed the trial under a strategic partnership on 30 patients across six sites in Sydney and regional New South Wales.

Noxopharm will continue to develop novel treatments for cancer and inflammation, including the production of new technology to enhance mRNA vaccines.

The company is partnering with leading researchers to build two new technology platforms Chroma (oncology) and Sofra (Inflammation, autoimmunity and mRNA vaccine enhancements) to advance medical technologies.

NOX last traded at 4.9 cents at 3:15 pm AEST.

NOX by the numbers
More From The Market Online

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

It’s hard to imagine a world without a mining company called Anglo American

Growing up in South Africa it seemed inconceivable that Anglo American, a mining colossus at its zenith…

Botanix isn’t sweating on FDA approval for Sofdra

Botanix has submitted the last label materials to the FDA seeking approval for Sofdra™ a prescription…